Cincinnati Children’s Innovative Platform Supporting Alzheimer's Disease Vaccine Development

Ohio-based Blue Water Vaccines Inc. recently announced it had entered into a Sponsored Research Agreement (the "SRA") with Cincinnati Children's Hospital Medical Center to explore vaccine development of its norovirus shell and protrusion platform for multiple diseases.

Currently, the platform is being utilized to develop BWV-301 for gastroenteritis caused by norovirus or rotavirus.

In a recent publication in Nano Research, titled "Bioengineered psuedovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity," Cincinnati Children's researchers hypothesized that this platform might represent a method to create novel influenza vaccines.

In addition, the SRA funds Cincinnati Children's research analyzing the applicability of this platform to develop a vaccine for Alzheimer's disease.

Preliminary research indicates the potential to develop a vaccine to target and inactivate amyloid-beta, which can accumulate and form plaques commonly associated with Alzheimer's disease.

This is important news since the U.S. FDA has not authorized an Alzheimer's vaccine as of July 22, 2022.

"This agreement is an important step toward developing vaccines against multiple diseases that affect millions of individuals each year," said Ming Tan, Ph.D., Associate Professor in the Division of Infectious Diseases and principal investigator of the study at Cincinnati Children's, in a press release issue don July 20, 2022.

Blue Water is headquartered in Cincinnati, OH, and holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital. 

Note: This media release was curated for mobile readers.